Publications in collaboration with researchers from Pierre and Marie Curie University (21)

2025

  1. Effects of anti-inflammatory therapy in acute heart failure: a systematic review and meta-analysis

    Heart Failure Reviews, Vol. 30, Núm. 3, pp. 575-587

2024

  1. Practical approach for atrial cardiomyopathy characterization in patients with atrial fibrillation

    Revista Espanola de Cardiologia, Vol. 77, Núm. 8, pp. 656-666

2023

  1. Association between common cardiovascular risk factors and clinical phenotype in patients with hypertrophic cardiomyopathy from the European Society of Cardiology (ESC) EurObservational Research Programme (EORP) Cardiomyopathy/Myocarditis registry

    European Heart Journal - Quality of Care and Clinical Outcomes, Vol. 9, Núm. 1, pp. 42-53

2022

  1. Author Correction: Genome-wide association analyses identify new Brugada syndrome risk loci and highlight a new mechanism of sodium channel regulation in disease susceptibility (Nature Genetics, (2022), 54, 3, (232-239), 10.1038/s41588-021-01007-6)

    Nature Genetics

  2. Genome-wide association analyses identify new Brugada syndrome risk loci and highlight a new mechanism of sodium channel regulation in disease susceptibility

    Nature genetics, Vol. 54, Núm. 3, pp. 232-239

  3. Impact of chronic coronary syndromes on cardiovascular hospitalization and mortality: the ESC-EORP CICD-LT registry

    European Journal of Preventive Cardiology, Vol. 29, Núm. 15, pp. 1945-1954

2021

  1. Association of Left Ventricular Systolic Dysfunction among Carriers of Truncating Variants in Filamin C with Frequent Ventricular Arrhythmia and End-stage Heart Failure

    JAMA Cardiology, Vol. 6, Núm. 8, pp. 891-901

  2. Current use of cardiac magnetic resonance in tertiary referral centres for the diagnosis of cardiomyopathy: The ESC EORP Cardiomyopathy/Myocarditis Registry

    European Heart Journal Cardiovascular Imaging, Vol. 22, Núm. 7, pp. 781-789

  3. Differences between familial and sporadic dilated cardiomyopathy: ESC EORP Cardiomyopathy & Myocarditis registry

    ESC Heart Failure, Vol. 8, Núm. 1, pp. 95-105

  4. Enhancing rare variant interpretation in inherited arrhythmias through quantitative analysis of consortium disease cohorts and population controls

    Genetics in Medicine, Vol. 23, Núm. 1, pp. 47-58

  5. Prospective follow-up in various subtypes of cardiomyopathies: Insights from the ESC EORP Cardiomyopathy Registry

    European Heart Journal - Quality of Care and Clinical Outcomes, Vol. 7, Núm. 2, pp. 134-142

2020

  1. Atrial fibrillation, anticoagulation management and risk of stroke in the Cardiomyopathy/Myocarditis registry of the EURObservational Research Programme of the European Society of Cardiology

    ESC Heart Failure, Vol. 7, Núm. 6, pp. 3601-3609

  2. Diagnosis and management of left atrial appendage thrombus in patients with atrial fibrillation undergoing cardioversion or percutaneous left atrial procedures: Results of the European Heart Rhythm Association survey

    Europace, Vol. 22, Núm. 1, pp. 162-169

2018

  1. Left atrial thrombus resolution in non-valvular atrial fibrillation or flutter: biomarker substudy results from a prospective study with rivaroxaban (X-TRA)

    Annals of Medicine, Vol. 50, Núm. 6, pp. 511-518

2017

  1. Antithrombotic Therapy in Atrial Fibrillation Associated with Valvular Heart Disease: Executive Summary of a Joint Consensus Document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, Endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE)

    Thrombosis and Haemostasis, Vol. 117, Núm. 12, pp. 2215-2236

  2. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: A joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE)

    Europace, Vol. 19, Núm. 11, pp. 1757-1758

2016

  1. Extraction of the Brachialis muscle activity using HD-sEMG technique and Canonical Correlation Analysis

    2016 38TH ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY (EMBC)

  2. Left atrial thrombus resolution in atrial fibrillation or flutter: Results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF)

    American Heart Journal, Vol. 178, pp. 126-134

  3. Prognostic significance of anaemia in patients with heart failure with preserved and reduced ejection fraction: Results from the MAGGIC individual patient data meta-analysis

    QJM, Vol. 109, Núm. 6, pp. 377-382

2015

  1. Rationale and design of a study exploring the efficacy of once-daily oral rivaroxaban (X-TRA) on the outcome of left atrial/left atrial appendage thrombus in nonvalvular atrial fibrillation or atrial flutter and a retrospective observational registry providing baseline data (CLOT-AF)

    American Heart Journal, Vol. 169, Núm. 4, pp. 464-471.e2